T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$2.6B |
| 2 |
BNY
Bank of New York Mellon
BNY
|
+$1.1B |
| 3 |
Elevance Health
ELV
|
+$903M |
| 4 |
DD
Du Pont De Nemours E I
DD
|
+$873M |
| 5 |
Medtronic
MDT
|
+$868M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$3.89B |
| 2 |
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
|
+$1.06B |
| 3 |
CFN
CAREFUSION CORPORATION
CFN
|
+$946M |
| 4 |
Aptiv
APTV
|
+$886M |
| 5 |
KSU
Kansas City Southern
KSU
|
+$662M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.05% |
| 2 | Consumer Discretionary | 13.82% |
| 3 | Financials | 13.14% |
| 4 | Industrials | 11.9% |
| 5 | Technology | 9.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
276
GSK
GSK
$101B
| $405M | 0.08% |
7,027,806
+325,276
| +5% | +$18.6M |
|
277
Pediatrix Medical
MD
$2.14B
| $402M | 0.08% |
5,541,826
+41,230
| +0.7% | +$2.87M |
|
278
Enovis
ENOV
$1.48B
| $401M | 0.08% |
4,879,770
+483,783
| +11% | +$40.5M |
|
279
Analog Devices
ADI
$186B
| $399M | 0.08% |
6,326,726
-21,005
| -0.3% | -$1.19M |
|
280
Deere & Co
DE
$165B
| $395M | 0.08% |
4,507,206
-28,410
| -0.6% | -$2.52M |
|
281
Tapestry
TPR
$25.9B
| $393M | 0.08% |
9,494,437
+2,879,167
| +44% | +$115M |
|
282
Neurocrine Biosciences
NBIX
$15.3B
| $392M | 0.08% |
9,877,839
-191,400
| -2% | -$6.85M |
|
283
Vornado Realty Trust
VNO
$7.41B
| $392M | 0.08% |
4,328,388
-382,318
| -8% | -$34.3M |
|
284
Conagra Brands
CAG
$7.39B
| $390M | 0.08% |
13,701,833
-1,283,787
| -9% | -$35.4M |
|
|
DFS
285
DELISTED
Discover Financial Services
DFS
| $388M | 0.08% |
6,886,489
+537,331
| +8% | +$31.8M |
|
286
Essex Property Trust
ESS
$18.5B
| $387M | 0.08% |
1,685,250
-5,448
| -0.3% | -$1.23M |
|
287
Oracle
ORCL
$450B
| $385M | 0.08% |
8,920,250
-411,818
| -4% | -$17.8M |
|
288
EOG Resources
EOG
$74.2B
| $384M | 0.08% |
4,183,892
-154,920
| -4% | -$14M |
|
289
Pacira BioSciences
PCRX
$924M
| $383M | 0.08% |
4,316,221
-61,430
| -1% | -$6.23M |
|
290
Federal Realty Investment Trust
FRT
$10.3B
| $382M | 0.08% |
2,596,420
+93,344
| +4% | +$13.4M |
|
|
TLM
291
DELISTED
TALISMAN ENERGY INC
TLM
| $380M | 0.08% |
49,536,661
-1,969,547
| -4% | -$15.1M |
|
292
Harley-Davidson
HOG
$2.9B
| $379M | 0.08% |
6,238,473
-3,943
| -0.1% | -$248K |
|
|
CLR
293
DELISTED
CONTINENTAL RESOURCES INC.
CLR
| $376M | 0.08% |
8,608,808
+2,025,638
| +31% | +$86.2M |
|
294
Allstate
ALL
$65.9B
| $375M | 0.08% |
5,274,451
-185,205
| -3% | -$13.1M |
|
|
SPLS
295
DELISTED
Staples Inc
SPLS
| $375M | 0.08% |
23,017,068
+28,230
| +0.1% | +$474K |
|
296
Occidental Petroleum
OXY
$57.7B
| $374M | 0.08% |
5,138,615
-122,210
| -2% | -$9.45M |
|
297
Wolverine World Wide
WWW
$1.63B
| $373M | 0.08% |
11,163,101
+892,080
| +9% | +$26.4M |
|
298
Equity Residential
EQR
$24.7B
| $370M | 0.08% |
4,750,235
+2,460
| +0.1% | +$192K |
|
299
Prologis
PLD
$134B
| $368M | 0.08% |
8,447,102
+28,450
| +0.3% | +$1.25M |
|
300
Lennox International
LII
$14.5B
| $366M | 0.08% |
3,279,920
+85,980
| +3% | +$8.87M |
|
Similar funds
T. Rowe Price Associates's Q1 2015 Portfolio in Review
As of Q1 2015, T. Rowe Price Associates held 2,630 positions worth $484B, up 2.8% from $471B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
T. Rowe Price Associates's Q1 2015 filing shows 93 new, 1,078 increased, 887 reduced and 93 closed positions. Its largest new stake was ACTAVIS PLC Pfd Conv Ser A (Irl): 516,600 shares worth $532M. The largest sale was Allergan Inc, an estimated $3.89B.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 20% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q1 2015 buy was ACTAVIS PLC Pfd Conv Ser A (Irl): 516,600 shares worth $532M.
- T. Rowe Price Associates added most to Allergan plc in Q1 2015, an estimated $2.6B increase.
- T. Rowe Price Associates's biggest Q1 2015 reduction was Aptiv, cutting an estimated $886M.
- T. Rowe Price Associates fully exited Allergan Inc in Q1 2015, selling an estimated $3.89B.
- T. Rowe Price Associates's ten largest holdings make up 13% of its $484B portfolio in Q1 2015.
- T. Rowe Price Associates opened 93 new positions and closed 93 in Q1 2015.
- T. Rowe Price Associates's portfolio value rose 2.8% quarter-over-quarter to $484B.
Based on T. Rowe Price Associates's 13F filing for Q1 2015, filed 15 May 2015.